News Image

Ligand Reports First Quarter 2025 Financial Results

Provided By GlobeNewswire

Last update: May 8, 2025

First quarter performance driven by strong portfolio royalty revenue growth of 44%

Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Creek Biosciences

Read more at globenewswire.com

LIGAND PHARMACEUTICALS

NASDAQ:LGND (8/8/2025, 8:00:02 PM)

After market: 150.06 0 (0%)

150.06

+3.74 (+2.56%)



Find more stocks in the Stock Screener

LGND Latest News and Analysis

Follow ChartMill for more